Results 121 to 130 of about 240,598 (262)

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Microsatellite‐stable (MSS) colorectal cancer (CRC) resists immunotherapy. PRMT5 inhibition enhances CPT‐11 sensitivity, inducing a PMS2‐deficient‐like state and cytosolic dsDNA release, which activates the cGAS‐STING pathway to promote anti‐tumor immunity. However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition
Jiang Zhu   +10 more
wiley   +1 more source

Dipyridamole Acts as Clinical Ferroptosis Inhibitor to Prevent from Tissue Injury

open access: yesAdvanced Science, EarlyView.
Dipyridamole acts as a clinically used compound to suppress ferroptosis. Dipyridamole down‐regulates the expression of RNF126, which is an E3 ligase to ubiquitinate SLC7A11 for proteasome degradation. The deficiency of SLC7A11 largely abolishes the protective role of dipyridamole both in vitro and in vivo.
Xiao Zhuang   +22 more
wiley   +1 more source

Wogonin Attenuates Atherosclerosis via KLF11‐Mediated Suppression of PPARα‐YAP1‐Driven Glycolysis and Enhancement of ABCA1/G1‐Mediated Cholesterol Efflux

open access: yesAdvanced Science, EarlyView.
PPARα promotes KLF11 expression and recruits KLF11 and YAP1 to form a transcription complex, where KLF11 acts as a brake in PPARα‐YAP1‐mediated glycolysis. Wogonin reshapes the metabolism of macrophages from glycolysis to fatty acid oxidation via activation of the PPARα‐KLF11‐YAP1 pathway, by which wogonin reduces inflammation and foam cell formation ...
Chuanrui Ma   +14 more
wiley   +1 more source

The interaction of aliphatic and aromatic dicarboxylic acids with aspartate aminotransferase [PDF]

open access: green, 1972
Harriet E. Harris   +3 more
openalex   +1 more source

Smart Organic–Inorganic Copolymer Nanoparticles Distinguish Between Microglia and Cancer Cells for Synergistic Immunotherapy in Glioma

open access: yesAdvanced Science, EarlyView.
The tumor microenvironment‐responsive nanoagonists are developed using an organic–inorganic copolymer composed of the polymer (PC6AB) and manganous phosphate ionic oligomers (MnP). PC6AB with membranolytic activity selectively interacts with tumor cell membranes to induce immunogenic cell death, while MnP activates the STING pathway in immune cells ...
Shiming Zhang   +14 more
wiley   +1 more source

Neoadjuvant Chemotherapy With Cisplatin Up‐Regulates GSDMD to Enhance Oral Squamous Cell Carcinoma Metastasis Through MMP14‐Mediated EMT Activation

open access: yesAdvanced Science, EarlyView.
Oral squamous cell carcinoma cells exhibit upregulated expression of GSDMD upon exposure to low‐dose cisplatin chemotherapy, which subsequently interacts with MMP14 through its N‐terminal domain, activating the epithelial‒mesenchymal transition (EMT) process and promoting the lymph node metastasis of oral squamous cell carcinoma.
Zixian Huang   +9 more
wiley   +1 more source

Responsive ROS‐Augmented Prodrug Hybridization Nanoassemblies for Multidimensionally Synergitic Treatment of Hepatocellular Carcinoma in Cascade Assaults

open access: yesAdvanced Science, EarlyView.
This study proposes a novel HCC therapy using CA‐4S2@ES‐Cu nanomedicines to amplify cuproptosis, enhancing chemotherapy and immunotherapy. CA‐4 and ES‐Cu synergistically inhibit tumor growth, induce immune responses, and reverse the immunosuppressive microenvironment, offering an effective multidimensional therapeutic strategy for HCC treatment ...
Yingjie Zeng   +16 more
wiley   +1 more source

Comparative analysis of two genomic regions among four strains of Buchnera aphidicola, primary endosymbiont of aphids.

open access: yes, 2004
Preliminary analysis of two selected genomic regions of Buchnera aphidicola BCc, the primary endosymbiont of the cedar aphid Cinara cedri, has revealed a number of interesting features when compared with the corresponding homologous regions of the three ...
Gil, Rosario   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy